Education
About Us
Working with TipRanks
Follow Us
MDxHealth (MDXH)
NASDAQ:MDXH
Earnings Data
Report Date
May 14, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.13Last Year’s EPS
-0.31Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 26, 2025
|% Change Since: -22.40%
|Next Earnings Date:May 14, 2025
Earnings Call Sentiment|Positive
The earnings call reflected strong revenue growth and improved financial performance, despite a decline in gross margins and increased operating expenses. The company expressed confidence in achieving its revenue and adjusted EBITDA goals for 2025, driven by increased test volumes and strategic execution.Company Guidance
During the MDxHealth Fourth Quarter and Full Year 2024 Earnings Call, the company provided guidance for 2025, projecting revenue in the range of $108 million to $110 million, targeting a 20% revenue growth. The company announced a Q4 2024 revenue of $24.7 million, a 28% increase from the previous year, and a full-year revenue growth of 28%. Total billable test volume for Q4 was approximately 24,000, with tissue-based tests like Confirm mdx and GPS showing a 50% increase in volume compared to the prior year. The liquid-based tests, including Select mdx, Resolve mdx, and Germline, exhibited a 10% year-over-year increase. MDxHealth aims to achieve a positive adjusted EBITDA in the first half of 2025 and highlighted a gross margin of 62.7% for Q4 2024. Cash and cash equivalents were reported at $46.8 million as of December 31, 2024. The company remains confident in its growth strategy without expanding its sales organization and emphasizes the sustainable adoption of its test menu.Strong Revenue Growth
Achieved Q4 and full-year revenue growth of 28%, reaching $24.7 million for Q4 2024, compared to $19.4 million in Q4 2023.
Increased Test Volumes
Q4 total billable volume was approximately 24,000 tests, representing a total test unit growth of 26%. Tissue-based tests grew 50% in Q4 and 31% for the full year.
Improved Financial Performance
Operating loss for Q4 declined 27% to $4.6 million, and net loss decreased 36% to $6.8 million, driven by increased gross profit and decreased financial expenses.
Positive Outlook for 2025
Confirmed revenue guidance of $108 million to $110 million for 2025 with a goal of delivering 20% revenue growth and achieving positive adjusted EBITDA in the first half of the year.
---
MDXH Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
MDXH Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 26, 2025 | $1.83 | $1.86 | +1.64% |
| Nov 06, 2024 | $2.08 | $2.09 | +0.48% |
| Aug 21, 2024 | $3.27 | $2.87 | -12.23% |
| May 01, 2024 | $2.50 | $2.67 | +6.80% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does MDxHealth (MDXH) report earnings?
MDxHealth (MDXH) is schdueled to report earning on May 14, 2025, TBA Not Confirmed.
What is MDxHealth (MDXH) earnings time?
MDxHealth (MDXH) earnings time is at May 14, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MDXH EPS forecast?
MDXH EPS forecast for the fiscal quarter 2025 (Q1) is -0.13.
---